Meiji Yasuda Life Insurance Co Raises Stock Position in DaVita Inc. (NYSE:DVA)

Meiji Yasuda Life Insurance Co lifted its holdings in shares of DaVita Inc. (NYSE:DVA) by 6.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,890 shares of the company’s stock after purchasing an additional 170 shares during the quarter. Meiji Yasuda Life Insurance Co’s holdings in DaVita were worth $400,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in DVA. 8 Knots Management LLC acquired a new stake in DaVita during the 4th quarter worth approximately $89,504,000. Doma Perpetual Capital Management LLC purchased a new position in DaVita in the fourth quarter valued at $53,076,000. Harvard Management Co. Inc. acquired a new position in DaVita during the 2nd quarter worth $55,115,000. Norges Bank purchased a new stake in DaVita during the 4th quarter worth about $36,626,000. Finally, Allianz Asset Management GmbH raised its position in DaVita by 63.9% in the 4th quarter. Allianz Asset Management GmbH now owns 548,642 shares of the company’s stock valued at $57,476,000 after purchasing an additional 213,992 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Insider Buying and Selling at DaVita

In other news, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Kathleen Alyce Waters sold 7,857 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the transaction, the insider now owns 83,011 shares of the company’s stock, valued at $12,137,038.31. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Michael David Staffieri sold 9,539 shares of the business’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the transaction, the chief operating officer now owns 241,945 shares in the company, valued at approximately $36,299,008.35. The disclosure for this sale can be found here. Over the last quarter, insiders sold 173,482 shares of company stock worth $27,387,069. 2.00% of the stock is owned by insiders.

DaVita Price Performance

Shares of NYSE:DVA opened at $163.16 on Thursday. DaVita Inc. has a 12 month low of $71.51 and a 12 month high of $166.04. The firm has a market capitalization of $14.31 billion, a P/E ratio of 18.54, a P/E/G ratio of 0.95 and a beta of 0.87. The company has a debt-to-equity ratio of 9.94, a current ratio of 1.16 and a quick ratio of 1.12. The company’s fifty day moving average price is $146.25 and its 200 day moving average price is $140.54.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.47 by $0.12. The business had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.15 billion. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The business’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.08 earnings per share. As a group, sell-side analysts predict that DaVita Inc. will post 9.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on DVA. TD Cowen upped their target price on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. StockNews.com lowered shares of DaVita from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 8th. UBS Group lifted their price objective on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Truist Financial raised their price target on DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Tuesday, August 20th. Finally, Bank of America upped their price objective on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $157.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.